Albireo Pharma is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 130 staff and has a trailing 12-month revenue of around $57.4 million.
Our top picks for where to buy Albireo Pharma stock
How to buy Albireo Pharma stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALBO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Albireo Pharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Albireo Pharma stock price (NASDAQ: ALBO)
Use our graph to track the performance of ALBO stocks over time.Albireo Pharma shares at a glance
Latest market close | $44.15 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $38.96 |
200-day moving average | $25.30 |
Wall St. target price | $42.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-6.66 |
Is it a good time to buy Albireo Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Albireo Pharma price performance over time
Historical closes compared with the close of $44.15 from 2023-03-02
1 week (2024-08-25) | N/A |
---|---|
1 month (2024-08-01) | N/A |
3 months (2024-06-01) | N/A |
6 months (2024-03-01) | N/A |
1 year (2023-09-01) | N/A |
---|---|
2 years (2022-09-02) | 156.84% |
3 years (2021-09-03) | 48.75% |
5 years (2019-09-05) | 72.73% |
Albireo Pharma financials
Revenue TTM | $57.4 million |
---|---|
Gross profit TTM | $39.2 million |
Return on assets TTM | -24.94% |
Return on equity TTM | -93.08% |
Profit margin | -228.51% |
Book value | $4.84 |
Market Capitalization | $915.9 million |
TTM: trailing 12 months
Albireo Pharma share dividends
We're not expecting Albireo Pharma to pay a dividend over the next 12 months.
Have Albireo Pharma's shares ever split?
Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.
Albireo Pharma share price volatility
Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 1.0356. This would suggest that Albireo Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Albireo Pharma overview
Albireo Pharma, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.
Frequently asked questions
nullWhat percentage of Albireo Pharma is owned by insiders or institutions?
Currently 3.61% of Albireo Pharma shares are held by insiders and 107.689% by institutions. How many people work for Albireo Pharma?
Latest data suggests 130 work at Albireo Pharma. When does the fiscal year end for Albireo Pharma?
Albireo Pharma's fiscal year ends in December. Where is Albireo Pharma based?
Albireo Pharma's address is: 10 Post Office Square, Boston, MA, United States, 02109 What is Albireo Pharma's ISIN number?
Albireo Pharma's international securities identification number is: US01345P1066 What is Albireo Pharma's CUSIP number?
Albireo Pharma's Committee on Uniform Securities Identification Procedures number is: 09064M105
More guides on Finder
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
6 stocks like Nvidia you need to consider
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Public vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question